颅内动脉瘤用纳米电纺覆膜支架初步实验研究

发布时间：2018-02-04 09:25

本文关键词： 颅内动脉瘤纳米电纺覆膜支架生物相容性力学性能　出处：《介入放射学杂志》2016年05期 　论文类型：期刊论文

【摘要】：目的动物实验研究评价新型颅内动脉瘤用纳米电纺覆膜支架的力学性能和生物相容性。方法 10只健康成年比格犬中共植入20枚纳米电纺覆膜支架,其中10枚0.10 mm丝径支架植入左侧锁骨下动脉(A组),10枚0.15 mm丝径支架植入右侧锁骨下动脉(B组)。支架植入术后即刻和术后2、4、6周分别作血管造影随访。支架段血管作组织学病理检查,评价支架内皮化和内膜增生情况。结果 A组支架植入后即刻造影示7枚支架内漏,随访期间2枚支架内漏消失,5枚仍残留内漏;B组支架植入后即刻造影示1枚支架内漏,随访期间内漏消失,3枚支架发生轻度狭窄(狭窄程度50%)。组织病理学检查显示,B组术后2周血管壁呈慢性炎性反应,术后4周支架内表面部分血管内皮化,术后6周支架内表面基本实现血管内皮化。结论本实验研究初步证明纳米电纺覆膜支架治疗颅内动脉瘤的有效性和可行性,具有重要临床应用价值。但该支架尚处于初始研究阶段,有待进一步远期观察和研究。
[Abstract]:Objective to evaluate the mechanical properties and biocompatibility of a novel nano-electrospun scaffold for intracranial aneurysms. Methods 20 nano-electrospun scaffolds were implanted into 10 healthy adult Beagle dogs. Ten 0.10mm wire diameter stents were implanted into the left subclavian artery (group A). Ten 0.15 mm wire diameter stents were implanted into right subclavian artery in group B. Angiography was performed immediately after stent implantation and 2 ~ 4 weeks after stent implantation. Results in group A, 7 stent leaks were found immediately after stent implantation, and 5 of them disappeared during the follow-up period. In group B, 1 stent leakage was detected immediately after stent implantation, and 3 stents with slight stenosis occurred during follow-up. Histopathological examination showed that there was slight stenosis in 3 stents. In group B, the vascular wall showed chronic inflammatory reaction 2 weeks after operation, and some vascular endothelialization on the inner surface of stent 4 weeks after operation. At 6 weeks after operation, vascular endothelialization was basically achieved on the inner surface of stent. Conclusion the feasibility and efficacy of nano-electrospun stent in the treatment of intracranial aneurysms were preliminarily proved. It has important clinical application value, but the stent is still in the initial stage of study, which needs further long-term observation and study.
【作者单位】：深圳市人民医院(暨南大学第二临床医学院)介入科;深圳市麦普奇科技发展有限公司;中国医科大学附属第一医院;
【基金】：深圳市科技研发资金技术研究开发计划(CXZZ20120618145240822)
【分类号】：R743.3;R318.08
【正文快照】： 颅内动脉瘤是蛛网膜下腔出血(SAH)主要病因,首次破裂出血后致残致死率可高达1/3[1-3]。颅内动脉瘤保守治疗无效需作开颅夹闭或血管内介入治疗[4-5]。目前认为血管内介入治疗颅内动脉瘤总体疗效好于开颅夹闭术,临床上首选介入治疗,但由于病理生理机制和解剖因素等,介入治疗仍存

【相似文献】